Get the Stockscreener App
2.64
8.20%
0.20
Pre-market:
2.82
0.18
+6.82%
Gain Therapeutics Inc Stock (GANX) Forecast
The Gain Therapeutics Inc (GANX) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $4.1552, representing a +57.40% increase from the current price of $2.64. The highest analyst price target is $4.0451, and the lowest is $4.2653.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month GANX Price Target
Average 4.6304
(+75.40% Upside)
Is Gain Therapeutics Inc (GANX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 67.78 | Neutral |
| STOCH(9,6) | 69.83 | Neutral |
| STOCHRSI(14) | 100.00 | Sell |
| MACD(12,26) | 0.0933 | Buy |
| ADX(14) | 20.58 | Neutral |
| William %R | -8.4175 | Sell |
| CCI(14) | 238.55 | Buy |
Buy: 2
Sell: 2
Neutral: 3
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
2.229
Buy
|
2.2941
Buy
|
| MA20 |
2.2315
Buy
|
2.2166
Buy
|
| MA50 |
1.9819
Buy
|
2.0887
Buy
|
| MA100 |
2.0194
Buy
|
2.0125
Buy
|
| MA200 |
1.8761
Buy
|
2.1767
Buy
|
Buy: 10
Sell: 0
Neutral: 0
Summary: Buy
According to our latest analysis, GANX could be considered a Strong Buy, with 17 technical analysis indicators signaling 12 Buy signals, 2 signaling Sell signals and 3 Neutral signals. This might be a good time to open fresh positions on GANX, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 67.78 indicates that GANX is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 69.83 indicates that GANX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 100 indicates that GANX is oversold. This suggests that GANX price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 20.58 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 238.55 indicates that GANX is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.
Long-term GANX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Gain Therapeutics Inc financial reports and earnings history, Gain Therapeutics Inc (GANX) stock could reach $8.378 by 2030, $35.78 by 2040 and $71.24 by 2050. See the projected annual prices until 2050 of the Gain Therapeutics Inc stock below:
- Gain Therapeutics Inc (GANX) is expected to reach an average price of $34.69 in 2035, with a high prediction of $34.00 and a low estimate of $33.17. This indicates an $1,214% rise from the last recorded price of $2.64.
- Gain Therapeutics Inc (GANX) stock is projected to chart a bullish course in 2040, with an average price target of $35.05, representing an $1,227% surge from its current level. The forecast ranges from a conservative $35.21 to a sky-high $35.78.
- Our analysts predict Gain Therapeutics Inc (GANX) to jump 679.35% by 2045, soaring from $20.71 to an average price of $20.57, potentially reaching $21.24. While $20.71 is the low estimate, the potential upside is significant.
- Gain Therapeutics Inc (GANX) stock is expected to climb by 2050, reaching an average of $71.78, a $2,619% jump from its current level. However, a wide range of estimates exists, with high and low targets of $71.24 and $71.66, respectively, highlighting the market's uncertainty.
Gain Therapeutics Inc Stock (GANX) Year by Year Forecast
Gain Therapeutics Inc Stock (GANX) Price Forecast for 2025
Gain Therapeutics Inc Stock (GANX) is expected to reach an average price of $3.888 in 2025, with a high prediction of $5.4919 and a low estimate of $2.284. This indicates an +47.27% rise from the last recorded price of $2.64.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| March, 2025 | $4.8901 | $4.2653 | $4.0451 | +85.23% |
| April, 2025 | $5.1614 | $5.2084 | $5.2549 | +95.51% |
| May, 2025 | $5.5045 | $5.5424 | $5.4162 | +108.50% |
| June, 2025 | $4.8076 | $5.0976 | $5.208 | +82.10% |
| July, 2025 | $5.2189 | $4.8458 | $4.9789 | +97.68% |
| August, 2025 | $5.5419 | $5.4444 | $5.4919 | +109.92% |
| September, 2025 | $4.585 | $5.0367 | $5.3952 | +73.67% |
| October, 2025 | $3.9563 | $4.4113 | $4.2798 | +49.86% |
| November, 2025 | $3.6094 | $3.7994 | $3.6746 | +36.72% |
| December, 2025 | $3.6207 | $4.0207 | $3.9242 | +37.15% |
Gain Therapeutics Inc Stock (GANX) Price Forecast for 2026
The predicted value for Gain Therapeutics Inc (GANX) in 2026 is set at an average of $2.1972. Estimates vary from a peak of $3.9303 to a trough of $0.4642, indicating an -16.77% surge from the present price of $2.64.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $4.0437 | $3.7689 | $3.8655 | +53.17% |
| February, 2026 | $3.7468 | $3.8018 | $3.9303 | +41.92% |
| March, 2026 | $3.7798 | $3.9016 | $3.7798 | +43.18% |
| April, 2026 | $3.4712 | $3.6246 | $3.7281 | +31.48% |
| May, 2026 | $2.5942 | $2.9142 | $3.3994 | -1.73% |
| June, 2026 | $2.1073 | $2.2972 | $2.213 | -20.18% |
| July, 2026 | $2.2786 | $1.9126 | $1.9255 | -13.69% |
| August, 2026 | $0.9516 | $1.1734 | $0.9469 | -63.95% |
| September, 2026 | $0.313 | $0.503 | $0.70 | -88.15% |
| October, 2026 | $0.346 | $0.6432 | $0.5678 | -86.89% |
| November, 2026 | $0.5891 | $0.4642 | $0.2691 | -77.69% |
| December, 2026 | $0.8404 | $0.5656 | $0.7305 | -68.17% |
Gain Therapeutics Inc Stock (GANX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Gain Therapeutics Inc (GANX) is $5.3662, with a high forecast of $10.61 and a low forecast of $0.1197. This indicates an +103.26% increase from the last price of $2.64.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $1.0834 | $1.1534 | $0.9052 | -58.96% |
| February, 2027 | $0.6965 | $1.0365 | $1.00 | -73.62% |
| March, 2027 | $1.1078 | $1.0676 | $0.9295 | -58.04% |
| April, 2027 | $1.1909 | $1.2343 | $1.0826 | -54.89% |
| May, 2027 | $1.5239 | $1.3191 | $1.4639 | -42.28% |
| June, 2027 | $0.2848 | $0.1652 | $0.8262 | -89.21% |
| July, 2027 | $0.6117 | $0.1197 | $0.8217 | -76.83% |
| August, 2027 | $1.4986 | $0.4234 | $2.1968 | -43.23% |
| September, 2027 | $1.2673 | $1.0073 | $2.2939 | -52.00% |
| October, 2027 | $0.5943 | $0.3393 | $1.3591 | -77.49% |
| November, 2027 | $8.98 | $0.353 | $8.45 | +240.15% |
| December, 2027 | $11.30 | $9.3765 | $10.61 | +328.13% |
Gain Therapeutics Inc Stock (GANX) Price Forecast for 2028
In 2028, Gain Therapeutics Inc (GANX) is projected to reach an average price of $13.47, with a high projection of $14.67 and a low estimate of $12.27. This indicates an +410.19% rise from the last price of $2.64.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $12.38 | $12.77 | $12.25 | +368.89% |
| February, 2028 | $12.17 | $12.96 | $12.37 | +361.17% |
| March, 2028 | $13.04 | $12.36 | $12.29 | +393.84% |
| April, 2028 | $13.65 | $14.12 | $13.63 | +417.18% |
| May, 2028 | $13.17 | $13.61 | $13.37 | +398.72% |
| June, 2028 | $13.68 | $13.47 | $13.25 | +418.27% |
| July, 2028 | $12.49 | $13.38 | $13.32 | +373.05% |
| August, 2028 | $13.24 | $12.27 | $12.27 | +401.56% |
| September, 2028 | $13.92 | $13.81 | $13.50 | +427.17% |
| October, 2028 | $15.00 | $13.93 | $14.44 | +468.31% |
| November, 2028 | $15.06 | $14.62 | $14.67 | +470.30% |
| December, 2028 | $14.20 | $14.71 | $14.57 | +437.96% |
Gain Therapeutics Inc Stock (GANX) Price Forecast for 2029
The 2029 price forecast for Gain Therapeutics Inc Stock (GANX) is $11.33 on average, with a high prediction of $13.92 and a low estimate of $8.7415. This represents an +329.27% increase from the previous price of $2.64.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $13.64 | $13.69 | $13.35 | +416.84% |
| February, 2029 | $14.40 | $14.03 | $13.62 | +445.49% |
| March, 2029 | $13.16 | $13.90 | $13.92 | +398.37% |
| April, 2029 | $12.64 | $12.71 | $12.73 | +378.90% |
| May, 2029 | $11.75 | $11.77 | $12.35 | +344.91% |
| June, 2029 | $11.71 | $11.56 | $11.39 | +343.63% |
| July, 2029 | $11.11 | $11.22 | $11.53 | +320.75% |
| August, 2029 | $11.28 | $11.47 | $11.21 | +327.29% |
| September, 2029 | $10.76 | $10.89 | $10.88 | +307.45% |
| October, 2029 | $10.33 | $10.35 | $10.66 | +291.26% |
| November, 2029 | $9.7954 | $9.8824 | $10.20 | +271.04% |
| December, 2029 | $8.6715 | $8.7415 | $8.9419 | +228.47% |
Gain Therapeutics Inc Stock (GANX) Price Forecast for 2030
Gain Therapeutics Inc Stock (GANX) is expected to reach an average price of $6.5845 in 2030, with a high forecast of $8.378 and a low forecast of $4.7909. This signifies an +149.41% surge from the last price of $2.64.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $7.9441 | $7.9646 | $8.378 | +200.91% |
| February, 2030 | $6.7902 | $7.1102 | $7.8207 | +157.21% |
| March, 2030 | $5.8463 | $6.5263 | $6.6468 | +121.45% |
| April, 2030 | $5.8925 | $5.9859 | $5.6229 | +123.20% |
| May, 2030 | $5.2951 | $5.6451 | $5.8955 | +100.57% |
| June, 2030 | $5.4912 | $5.5312 | $5.3381 | +108.00% |
| July, 2030 | $5.8938 | $5.5277 | $5.5638 | +123.25% |
| August, 2030 | $5.6499 | $5.6899 | $5.5604 | +114.01% |
| September, 2030 | $5.3061 | $5.433 | $5.2465 | +100.99% |
| October, 2030 | $5.2087 | $5.2571 | $5.0987 | +97.30% |
| November, 2030 | $5.4948 | $5.1983 | $5.0652 | +108.14% |
| December, 2030 | $4.7409 | $4.7909 | $5.2213 | +79.58% |
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):